Company / Free Cash Flow
Actinium Pharmaceuticals, Inc. Free Cash Flow History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$24.7M
FY2025
5-year range
-$47.5M / $8.3M
FY2021-FY2025
Trend
+48.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $8M to -$25M over the past 2 years.
Based on SEC 10-K filings.
-$25M in FY2025.
Declined from $8M to -$25M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow increased 48.0% year-over-year.
- Peak free cash flow was recorded in FY2023.
- Lowest free cash flow in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$24.7M | +48.0% |
| FY2024 | -$47.5M | -673.7% |
| FY2023 | $8.3M | +139.4% |
| FY2022 | -$21.0M | +4.0% |
| FY2021 | -$21.9M | - |
| FY2011 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026